DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage response-related mutations. The trial has begun testing a twice daily dosing regimen, starting with 550 mg twice daily, to optimize therapeutic drug levels and potentially improve outcomes.
The move to twice daily dosing reflects evidence suggesting that more frequent administration of ATRN-119 could enhance efficacy by providing better 24-hour target coverage. The revised protocol positions ATRN-119 as the only ATR inhibitor in clinical trials to use a continuous twice daily schedule as monotherapy.
“Twice daily dosing represents a proactive step to de-risk the trial, potentially increasing the probability of success,” said Oren Gilad, Ph.D., President and CEO of Aprea. “It highlights our commitment to scientific excellence and strengthens ATRN-119’s differentiation as a high-value program.”
Anthony Tolcher, M.D., CEO of NEXT Oncology and a study investigator, also emphasized the promise of ATR inhibition. “This mechanism holds considerable potential for patients with difficult-to-treat cancers. A twice daily regimen could maximize the therapeutic potential of ATRN-119.”
The study will continue to evaluate both once and twice daily dosing schedules independently, focusing on safety, tolerability, and pharmacokinetics. A preliminary Phase 1 trial readout is expected in the second half of 2025.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.